Larimar Therapeutics Statistics Share Statistics Larimar Therapeutics has 85.59M
shares outstanding. The number of shares has increased by 34.14%
in one year.
Shares Outstanding 85.59M Shares Change (YoY) 34.14% Shares Change (QoQ) 33.68% Owned by Institutions (%) 94.11% Shares Floating 43.14M Failed to Deliver (FTD) Shares 50 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 7.65M, so 8.94% of the outstanding
shares have been sold short.
Short Interest 7.65M Short % of Shares Out 8.94% Short % of Float 13.44% Short Ratio (days to cover) 5.82
Valuation Ratios The PE ratio is -2.94 and the forward
PE ratio is -2.5.
Larimar Therapeutics's PEG ratio is
-0.05.
PE Ratio -2.94 Forward PE -2.5 PS Ratio 0 Forward PS 179.9 PB Ratio 1.38 P/FCF Ratio -3.33 PEG Ratio -0.05
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Larimar Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 8.02,
with a Debt / Equity ratio of 0.03.
Current Ratio 8.02 Quick Ratio 8.02 Debt / Equity 0.03 Debt / EBITDA -0.06 Debt / FCF -0.07 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.24M Employee Count 65 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -26.77% in the
last 52 weeks. The beta is 1, so Larimar Therapeutics's
price volatility has been higher than the market average.
Beta 1 52-Week Price Change -26.77% 50-Day Moving Average 3.94 200-Day Moving Average 3.16 Relative Strength Index (RSI) 58.51 Average Volume (20 Days) 2,274,573
Income Statement
Revenue n/a Gross Profit -318K Operating Income -90.89M Net Income -80.6M EBITDA -80.29M EBIT -80.6M Earnings Per Share (EPS) -1.32
Full Income Statement Balance Sheet The company has 33.22M in cash and 5.12M in
debt, giving a net cash position of 28.1M.
Cash & Cash Equivalents 33.22M Total Debt 5.12M Net Cash 28.1M Retained Earnings -269.16M Total Assets 149.99M Working Capital 118.91M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -70.76M
and capital expenditures -515K, giving a free cash flow of -71.28M.
Operating Cash Flow -70.76M Capital Expenditures -515K Free Cash Flow -71.28M FCF Per Share -1.16
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields LRMR does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for LRMR is $18,
which is 269.6% higher than the current price. The consensus rating is "Buy".
Price Target $18 Price Target Difference 269.6% Analyst Consensus Buy Analyst Count 7
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 29, 2020. It was a
backward
split with a ratio of 1:12.
Last Split Date May 29, 2020 Split Type backward Split Ratio 1:12
Scores Altman Z-Score 3.17 Piotroski F-Score 2
